Aptose Biosciences Files 8-K with Regulatory Updates
Ticker: APTOF · Form: 8-K · Filed: Aug 18, 2025 · CIK: 882361
Sentiment: neutral
Topics: 8-K, regulatory-filing, financials
Related Tickers: APTO
TL;DR
APTO filed an 8-K on Aug 18, 2025, covering Reg FD and financials. Check for updates.
AI Summary
Aptose Biosciences Inc. filed an 8-K on August 18, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and operates in the Biological Products sector. The filing details its business address in Toronto, Ontario.
Why It Matters
This filing provides essential updates on Aptose Biosciences' regulatory compliance and financial reporting, which are crucial for investors to assess the company's current status and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of regulatory and financial information, not indicating any immediate operational or financial distress.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former Company Name
- Imutec Pharma Inc (company) — Former Company Name
- August 18, 2025 (date) — Date of Report
FAQ
What specific events are covered under the Regulation FD Disclosure?
The filing indicates a Regulation FD Disclosure but does not specify the exact events within this 8-K document.
What types of financial statements and exhibits are included in this filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific contents are not detailed in the provided header information.
When was Aptose Biosciences Inc. formerly known as Lorus Therapeutics Inc.?
The date of the name change from Lorus Therapeutics Inc. to Aptose Biosciences Inc. was September 5, 2014.
What is Aptose Biosciences Inc.'s Standard Industrial Classification code?
Aptose Biosciences Inc. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with the SIC code 2836.
Where is Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. is incorporated in Canada.
Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2025-08-18 08:00:46
Filing Documents
- f8k_081825.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 22KB
- 0001171843-25-005463.txt ( ) — 233KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_081825_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On August 18, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated August 18, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: August 18, 2025 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer